Clinical Trials Browser

Recruiting × Recurrence × Plasma cell × Clear all

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT05652335 2026-03-13

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Phase 1 Recruiting

Amyloidosis, Multiple Myeloma, Recurrence

NCT06604715 2026-03-13

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT06832865 2026-03-12

ELISA in Relapsed/Refractory MM

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT05519085 2026-03-11

SUCCESSOR-1

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT06375044 2026-03-06

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT05927571 2026-03-05

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT07280013 2026-03-05

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Phase 1 Recruiting

Bites and Stings, Multiple Myeloma, Recurrence

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT07116616 2026-02-24

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT05530421 2026-02-23

SELVEDge

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT03761108 2026-02-11

LINKER-MM1

Phase 1/2 Recruiting

387 enrolled 1 FDA

Multiple Myeloma, Recurrence

NCT06297226 2026-02-10

QUINTESSENTIAL

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT06215118 2026-02-05

MagnetisMM-30

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT06574568 2026-02-05

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT07369895 2026-01-27

Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT05675449 2026-01-26

MagnetisMM-20

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT05714839 2026-01-23

DREAMM-20

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT05922501 2026-01-14

ISABELA

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT07312188 2025-12-31

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT06827860 2025-12-18

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT06518551 2025-12-11

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT06251076 2025-12-10

Plan Development for Giving Teclistamab in the Outpatient Setting

Phase 4 Recruiting

Multiple Myeloma, Neoplasms, Recurrence

NCT07003555 2025-11-26

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT07003568 2025-11-26

Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT06421675 2025-11-14

EMBRACE

Phase 2 Recruiting

Cytokine Release Syndrome, Multiple Myeloma, Recurrence

NCT04176718 2025-10-07

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT06292780 2025-09-18

LINKER-AL2

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT05565807 2025-08-15

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT05913804 2025-08-15

YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT06961669 2025-05-29

ECAR01

Phase NA Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06971380 2025-05-14

Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis

Phase 2 Recruiting

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Recurrence

NCT06484829 2025-04-02

Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT06561854 2024-12-18

FREEDOM

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT06732232 2024-12-13

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

Phase EARLY_PHASE1 Recruiting

Multiple Myeloma, Recurrence

NCT06718270 2024-12-12

a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

Phase EARLY_PHASE1 Recruiting

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Recurrence

NCT06581640 2024-09-25

Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT04771572 2024-04-24

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Phase 1 Recruiting

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT06232096 2024-03-15

A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT06084962 2023-10-16

A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT05594797 2022-12-09

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT04603872 2020-10-28

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Phase EARLY_PHASE1 Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma